Tag Archives: Merck & Co.

Merck (MRK) 23Q3 Update

23Q3 sales increased 3.0% to $16.0 billion.  Excluding currency and sales of Lagevrio, sales rose 8%.  The sales gain came from an increase of $0.9 billion in Keytruda and $290 million in Gardasil.

Posted in Health Care, MRK | Tagged , | Comments Off on Merck (MRK) 23Q3 Update

Merck & Co. (MRK) 23Q2 Update

23Q2 sales increased 4.2% to $14.5 billion, but rose 11% excluding Lagevrio, a COVID-19 medicine.  The sales gain ex-Lagevrio was due to sales increases of $1 billion in Keytruda and $800 million in Gardasil.

Posted in Health Care, MRK | Tagged , | Comments Off on Merck & Co. (MRK) 23Q2 Update

Merck (MRK) 23Q1 Update

23Q1 sales fell 9.8% to $14.5 billion, but rose 13.5% excluding Lagevrio, a COVID-19 medicine whose sales have fallen sharply as the pandemic has receded.  The sales gain ex-Lagevrio was due entirely to a $1 billion increase in Keytruda sales … Continue reading

Posted in Health Care, MRK | Tagged , | Comments Off on Merck (MRK) 23Q1 Update

Merck & Co., Inc. 22Q4 Update

22Q4 sales rose 2.2% to $13.8 billion, as a 19.6% gain in KEYTRUDA was mostly offset by declines in Gardasil, Lagevrio and Januvia/Janumet, among others.  GAAP diluted EPS declined 21.3% to $1.19 and non-GAAP diluted EPS declined 15.0% to $1.53.  … Continue reading

Posted in Health Care, MRK | Tagged , | Comments Off on Merck & Co., Inc. 22Q4 Update

Merck & Co (MRK) 22Q3 Update

22Q3 sales rose 13.7% to $15.0 billion with double-digit gains in KEYTRUDA and GARDASIL/GARDASIL 9.  GAAP diluted EPS fell 29.0% to $1.28; but non-GAAP diluted EPS rose 5.6% to $1.85.  The company recorded an $887 million ($0.27 per share) asset … Continue reading

Posted in Health Care, MRK | Tagged , | Comments Off on Merck & Co (MRK) 22Q3 Update

Merck & Co (MRK) 22Q2 Update

22Q2 sales increased 28% to $14.6 billion, with LAGEVRIO sales of $1.2 billion, a 26% increase in KEYTRUDA sales to $5.3 billion and a 36% increase in GARDASIL/GARDASIL 9 sales to $1.7 billion.  GAAP diluted EPS from continuing operations increased … Continue reading

Posted in Health Care, MRK | Tagged , | Comments Off on Merck & Co (MRK) 22Q2 Update

Merck & Co. (MRK) Update

Establishing 2022 and 2023 Estimates, Maintaining Outperform Rating, Setting $85 Price Target Following the spin-off of Organon, Merck is focused on growing its pharmaceuticals business to offset the looming loss of exclusivity on its $5 billion Januvia/Janumet franchise and others … Continue reading

Posted in Health Care, MRK | Tagged , | Comments Off on Merck & Co. (MRK) Update

Assessing the Impact of the Organon Spin-Off on Merck

Merck is progressing toward the spin-off of its subsidiary, Organon & Co., which is expected to be completed by the end of the June.  Organon will include Merck’s women’s health products, biosimilars and certain established brands, most of which have … Continue reading

Posted in Health Care, MRK, OGN | Tagged , , , | Comments Off on Assessing the Impact of the Organon Spin-Off on Merck